External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Entero Healthcare Solutions Limited / Equity Bottom-Up

Entero Healthcare Solutions Limited (2294842D IN)

<ul><li>We recently interacted with Entero's senior management</li><li>The key highlights were: (1) In FY25, the company expects 35-40% revenue growth, with ~15-16% organic growth (outperforming IPM by 1.5x) and the remaining growth coming from acquisitions (targets ~INR 10 bn annualised sales from in FY25)</li><li>Over the mid-to-long term, the company aims to outperform IPM by 2x</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We recently interacted with Entero's senior managementThe key highlights were: (1) In FY25, the company expects 35-40% revenue growth, with ~15-16% organic growth (outperforming IPM by 1.5x) and the remaining growth coming from acquisitions (targets ~INR 10 bn annualised sales from in FY25)Over the mid-to-long term, the company aims to outperform IPM by 2xContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Entero Healthcare Solutions: Well-Placed to Consolidate Pharma Distribution. NOT RATED